News from the debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 07, 2014, 08:00 ET

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 30, 2014, 08:00 ET

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now...

Sep 26, 2014, 03:00 ET

Presented by the Japanese Cancer Association and Debiopharm Group™, the 'JCA-Mauvernay Award 2014' goes to Doctors Hara and Shibata

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Sep 17, 2014, 03:00 ET

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to congratulate Biocartis commitment in shipping its first...

Sep 04, 2014, 07:00 ET

Debiopharm Group™'s Innovative Antibiotic Debio 1450 - Developed From its Proprietary Platform Fabiotics - Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical...

Jun 26, 2014, 11:00 ET

Debiopharm Group and Nobelex Biotech Start Two Collaborations on Development of New Antibiotics Against N. Gonorrhoeae and Enteric Species

Debiopharm Group™ (Debiopharm), a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet...

Jun 24, 2014, 11:00 ET

Debiopharm Group and TCG Lifesciences Ltd. Announce Successful Completion of First Phase of Research Collaboration on Discovery of Novel Antibiotics

Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription...

May 28, 2014, 08:00 ET

Debiopharm Group™ Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs...

May 27, 2014, 02:00 ET

Orient EuroPharma and Debiopharm Group™ Announce Their Partnership and the Launch of Pamorelin® LA in Singapore

Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries...

May 06, 2014, 03:00 ET

Debiopharm Group™ and Yale University extend and broaden their collaboration for the discovery and development of MIF inhibitors to treat autoimmune and inflammatory diseases

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs...

Apr 08, 2014, 03:30 ET

Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014

Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and...

Apr 02, 2014, 01:30 ET

Evotec and Debiopharm Group™ to Collaborate on Development of New Treatment for Cancer

   - Innovative partnership based on Evotec's Target X projects  - Evotec and Debiopharm to share discovery and...

Mar 06, 2014, 03:00 ET

Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of...

Mar 05, 2014, 09:00 ET

Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™

Immunexpress Group (Immunexpress) and Debiopharm Diagnostics SA (Debiopharm), today announced the securing of six million U.S. dollars from a...

Feb 11, 2014, 09:00 ET

Debiopharm Group to Acquire Affinium's Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs...

Jan 13, 2014, 11:30 ET

Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

Jan 08, 2014, 03:00 ET

Spinomix Announces a Milestone Payment from Debiopharm Group™and the Appointment of a new CEO

Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm...

Oct 24, 2013, 11:00 ET

Atheris and Debiopharm Group™ to Collaborate for the Lead Optimization of Debio 0826 Using a "Reverse-Discovery" Strategy

Atheris Laboratories, a world leading company in venom-based drug discovery and lead optimization, and Debiopharm Group™ (Debiopharm), a...

Oct 22, 2013, 08:25 ET

Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor®)

Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and...

Oct 07, 2013, 03:00 ET

Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate for the Development of an Epigenetic Innovative Oncology Target

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and...